Skip to main content

Table 3 Predictors of LUNDEX-corrected EULAR good response. Odds ratios (95% confidence intervals)

From: Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

 6 months12 months
UnivariateMultivariateUnivariateMultivariate
Male sex2.11 (1.41–3.13)2.28 (1.45–3.57)2.46 (1.71–3.54)2.14 (1.44–3.19)
≥ 2 bDMARDsReference (1.0)Reference (1.0)Reference (1.0)Reference (1.0)
Bionaïve4.00 (2.60–6.15)3.59 (2.25–5.72)4.45 (2.95–6.71)4.29 (2.77–6.65)
1 bDMARD1.11 (0.72–1.72)*1.11 (0.74–1.69)**
DAS28-CRP (per SD) at baseline0.95 (0.80–1.14)*0.98 (0.83–1.16)**
DAS28 (per unit) at baseline0.91 (0.79–1.04)*0.97 (0.85–1.10)**
VAS pain (per SD) at baseline0.96 (0.80–1.15)*0.89 (0.75–1.06)**
Methotrexate at baseline1.36 (0.95–1.94)*1.46 (1.04–2.06)**
HAQ score (per SD) at baseline0.64 (0.52–0.77)0.75 (0.61–0.93)0.65 (0.54–0.78)0.74 (0.61–0.90)
Disease duration (per SD) at baseline0.79 (0.65–0.96)*0.72 (0.59–0.87)**
Age (per SD) at baseline0.76 (0.65–0.91)0.79 (0.65–0.96)0.97 (0.82–1.14)**
Glucocorticoids at baseline0.59 (0.42–0.83)0.59 (0.40–0.86)0.72 (0.52–1.00)**
csDMARD at baseline1.40 (0.96–2.06)*1.25 (0.87–1.79)**
s.c. abatacept administrationReference (1.0)*Reference (1.0)**
i.v. abatacept administration0.53 (0.38–0.75)*0.70 (0.51–0.98)**
  1. *Not included in the final model. The first multivariate model in the stepwise analysis included sex, bDMARD exposure, DAS28, methotrexate at baseline, HAQ-DI, disease duration, age, glucocorticoids at baseline, csDMARDs at baseline, and route of abatacept administration. **Not included in the final model. The first multivariate model in the stepwise analysis included sex, bDMARD exposure, methotrexate at baseline, HAQ-DI, disease duration, glucocorticoids at baseline, and route of abatacept administration. Multivariate model includes 754 patients at 6 months, 829 patients at 12 months